{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:06:21Z","timestamp":1790809581369,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007109","name":"May and Samuel Rudin Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acne is a common skin condition, but little data exist on the comparative efficacy of topical acne therapies. We conducted a systematic review and network meta\u2010analysis to evaluate the efficacy of topical therapies for mild\u2010to\u2010moderate acne. Searches in PubMed\/MEDLINE, Cochrane CENTRAL via Ovid, Embase via Ovid and Web of Science were conducted on 29 November 2021. Randomized controlled trials examining \u226512\u2009weeks of topical treatments for acne vulgaris in subjects aged 12 and older were included. Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale. Thirty\u2010five randomized clinical trials with 33,472 participants comparing nine different topical agents were included. Adapalene\u2010benzoyl peroxide (BPO), clindamycin\u2010BPO and clindamycin\u2010tretinoin demonstrated the greatest reduction in non\u2010inflammatory (ratio of means [RoM] 1.76; 95% CI [1.46; 2.12], RoM 1.70; 95% CI [1.44; 2.02] and RoM 1.87; 95% CI [1.53; 2.30], respectively), inflammatory (RoM 1.56; 95% CI [1.44; 1.70], RoM 1.49; 95% CI [1.39; 1.60] and RoM 1.48; 95% CI [1.36; 1.61], respectively) and total lesion count (ROM 1.67; 95% CI [1.47; 1.90], RoM 1.59; 95% CI [1.42; 1.79] and RoM 1.64; 95% CI [1.42; 1.89], respectively) compared to placebo. All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non\u2010inflammatory lesion count reduction. Most combination agents significantly outperformed their individual components in lesion count reduction and global assessment scores, except for clindamycin\u2010tretinoin and clindamycin\u2010BPO, which did not significantly outperform tretinoin (RoM 1.13; 95% CI [0.94; 1.36]) and BPO (RoM\u2009=\u20091.15, 95% CI [0.98; 1.36]), respectively, for non\u2010inflammatory lesion reduction. There was no significant difference amongst most single agents when evaluating lesion count reduction. Combination agents are generally most effective for mild\u2010to\u2010moderate acne; however for non\u2010inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.<\/jats:p>","DOI":"10.1111\/jdv.20154","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T03:54:40Z","timestamp":1719633280000},"page":"775-784","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of topical treatments for mild\u2010to\u2010moderate acne: A systematic review and meta\u2010analysis of randomized control trials"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6959-1385","authenticated-orcid":false,"given":"Efe E.","family":"Kakpovbia","sequence":"first","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Milam","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhi","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Population Health New York University Grossman School of Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie","family":"Yassin","sequence":"additional","affiliation":[{"name":"Department of Population Health New York University Grossman School of Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Nicholson","sequence":"additional","affiliation":[{"name":"NYU Health Sciences Library NYU Grossman School of Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Population Health New York University Grossman School of Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Troxel","sequence":"additional","affiliation":[{"name":"Department of Population Health New York University Grossman School of Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle R.","family":"Nagler","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12149"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70442-6"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13191"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14374"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13675"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_10_11_1","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2021"},{"key":"e_1_2_10_12_1","unstructured":"R\u00fcckerG SchwarzerG KrahnU K\u00f6nigJ SchwarzerMG.Network meta\u2010analysis using frequentist methods (Version 07\u20100). 2023."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546631003681094"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.040"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.046"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.10.005"},{"issue":"4","key":"e_1_2_10_19_1","first-page":"438","article-title":"The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle\u2010controlled, double\u2010blind studies","volume":"12","author":"Feldman SR","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_10_20_1","unstructured":"(NCT02886715). National Library of Medicine. A Study Comparing Tazarotene Cream 0.1% to TAZORAC\u00ae (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris. Published 2016. [cited 2019 Jul 1]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT02886715"},{"key":"e_1_2_10_21_1","unstructured":"ClinicalTrials.gov.Clinical study to test the efficacy and safety of adapalene NNLoMhcgcsNtN."},{"key":"e_1_2_10_22_1","unstructured":"ClinicalTrials.gov.Evaluation of quality of life E and tolerance of Duac\u00ae gel compared to Differin\u00ae gel in the treatment of acne (NCT00807014). National Library of Medicine. Published 2008. [cited 2019 Jul 1]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00807014?term=NCT00807014&draw=2&rank=1"},{"key":"e_1_2_10_23_1","unstructured":"ClinicalTrials.gov.Study STF115287 a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects."},{"key":"e_1_2_10_24_1","unstructured":"A Study to Demonstrate the Efficacy and Safety of Adapalene\/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris. [cited 2021 Nov 30]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT00421993"},{"issue":"2","key":"e_1_2_10_25_1","first-page":"152","article-title":"A double\u2010blinded, randomized, vehicle\u2010controlled, multicenter, parallel\u2010group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults","volume":"80","author":"Berger R","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1720579"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0352-y"},{"issue":"12","key":"e_1_2_10_28_1","first-page":"1382","article-title":"Safety and efficacy of clindamycin phosphate 1.2%\u2010benzoyl peroxide 3% fixed\u2010dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double\u2010blind, active\u2010 and vehicle\u2010controlled study","volume":"10","author":"Eichenfield LF","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"e_1_2_10_29_1","first-page":"110","article-title":"A north American study of adapalene\u2010benzoyl peroxide combination gel in the treatment of acne","volume":"84","author":"Gold LS","year":"2009","journal-title":"Cutis"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09209.x"},{"issue":"3","key":"e_1_2_10_31_1","first-page":"318","article-title":"Efficacy and safety of clindamycin\u2010tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double\u2010blind, vehicle\u2010controlled study","volume":"11","author":"Jarratt MT","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"e_1_2_10_32_1","first-page":"105","article-title":"Efficacy and tolerability of adapalene 0.1%\u2010benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in indian patients: a randomized investigator\u2010blind controlled trial","volume":"19","author":"Jawade SASV","year":"2016","journal-title":"Iran J Dermatol"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12580"},{"issue":"6","key":"e_1_2_10_34_1","first-page":"s18","article-title":"Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris","volume":"7","author":"Pariser D","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"e_1_2_10_35_1","first-page":"1083","article-title":"An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once\u2010daily treatment of moderate to severe acne vulgaris","volume":"13","author":"Pariser DM","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"e_1_2_10_36_1","first-page":"31","article-title":"Clindamycin 1.2% Tretinoin 0.025% gel versus clindamycin gel treatment in acne patients: a focus on Fitzpatrick skin types","volume":"4","author":"Schmidt N","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"e_1_2_10_37_1","first-page":"48","article-title":"The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris","volume":"4","author":"Shalita AR","year":"2005","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"e_1_2_10_38_1","first-page":"553","article-title":"Efficacy and safety of once\u2010daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle\u2010controlled trials","volume":"15","author":"Stein Gold LF","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"e_1_2_10_39_1","first-page":"549","article-title":"Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris","volume":"9","author":"Tanghetti E","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"e_1_2_10_40_1","first-page":"s3","article-title":"Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris","volume":"7","author":"Thiboutot D","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.006"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13622"},{"issue":"4","key":"e_1_2_10_43_1","first-page":"223","article-title":"Study of the efficacy, tolerability, and safety of 2 fixed\u2010dose combination gels in the management of acne vulgaris","volume":"84","author":"Zouboulis CC","year":"2009","journal-title":"Cutis"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00527-7"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4944"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20080"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:59:54Z","timestamp":1744253994000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/jdv.20154"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20154","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,29]]},"assertion":[{"value":"2023-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}